Anti-TPBG / Trophoblast glycoprotein

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. TPBG antibody detects Trophoblast glycoprotein, a highly glycosylated cell surface protein involved in cell adhesion, signal transduction, and immune regulation. Also known as 5T4 oncofetal antigen, TPBG is a type I transmembrane glycoprotein expressed in trophoblasts and upregulated in many carcinomas. The TPBG antibody is used extensively in cancer biology, immunology, and stem cell research to study tumor invasion, metastasis, and cell differentiation mechanisms regulated by this protein.TPBG is encoded by the TPBG gene located on human chromosome 6q14.1. The mature protein is approximately 420 amino acids long and features an N-terminal signal peptide, several leucine-rich repeats, and an immunoglobulin-like domain in its extracellular region. It is anchored to the plasma membrane through a single transmembrane helix and contains a short cytoplasmic tail. Physiologically, TPBG modulates cell-cell interactions in placental development and embryo implantation, while pathologically, it is re-expressed in many epithelial tumors, where it contributes to epithelial-mesenchymal transition (EMT) and metastatic behavior.The TPBG antibody is commonly used in immunohistochemistry and flow cytometry to identify tumor cells expressing the 5T4 antigen. Elevated TPBG expression has been reported in lung, ovarian, colorectal, and pancreatic cancers and is associated with poor prognosis and increased invasiveness. The protein influences Wnt/beta-catenin and CXCR4 signaling pathways, promoting migration and stem-like phenotypes. Western blot typically shows a broad band between 72-80 kDa, reflecting heavy glycosylation. Immunofluorescence microscopy reveals localization along the plasma membrane and at cell junctions.In stem cell research, TPBG expression marks the transition from pluripotency to differentiation, making it a useful biomarker in embryonic stem cell studies. It modulates cytoskeletal dynamics and cell polarity through interactions with intracellular adaptors. Therapeutically, TPBG serves as a target for cancer immunotherapies, including antibody-drug conjugates and vaccines under clinical evaluation. NSJ Bioreagents provides a validated TPBG antibody optimized for western blot, flow cytometry, and immunohistochemistry, enabling reliable detection of this tumor-associated glycoprotein and supporting ongoing efforts in oncology and regenerative medicine research.